Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model

Author： Lahu Gezim   Hünnemeyer Andreas  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.49, Iss.9, 2010-09, pp. : 589-606

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of Fluvoxamine on the Pharmacokinetics of Roflumilast and Roflumilast N -Oxide

By Oliver von Richter  

Clinical Pharmacokinetics, Vol. 46, Iss. 7, 2007-01 ,pp. : 613-622

Adis International

Access to resources Recommend Favorite

Pharmacokinetic evaluation of roflumilast

By Lahu Gezim   Nassr Nassr   Hünnemeyer Andreas  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 12, 2011-12 ,pp. : 1577-1591

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease

By Doggrell Sheila A  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 4, 2006-03 ,pp. : 485-488

Informa Healthcare

Access to resources Recommend Favorite

Steady-State Pharmacokinetics of Roflumilast and Roflumilast N -Oxide in Patients with Mild and Moderate Liver Cirrhosis

By Hermann Robert  

Clinical Pharmacokinetics, Vol. 46, Iss. 5, 2007-01 ,pp. : 403-416

Adis International

Access to resources Recommend Favorite

Population Pharmacokinetics of Cycloplatam. I. Development of the Population Model for Description of the Pharmacokinetic and Pharmacodynamic Processes Involving Cycloplatam

By Singin A. S.  

Pharmaceutical Chemistry Journal, Vol. 37, Iss. 10, 2003-10 ,pp. : 513-517

Springer Publishing Company

Access to resources Recommend Favorite